558 related articles for article (PubMed ID: 29454091)
1. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1.
Lin B; Song X; Yang D; Bai D; Yao Y; Lu N
Gene; 2018 May; 654():77-86. PubMed ID: 29454091
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
4. TKI-31 inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFRbeta.
Zhong L; Guo XN; Zhang XH; Sun QM; Tong LJ; Wu ZX; Luo XM; Jiang HL; Nan FJ; Zhang XW; Lin LP; Ding J
Cancer Biol Ther; 2006 Mar; 5(3):323-30. PubMed ID: 16575201
[TBL] [Abstract][Full Text] [Related]
5. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR.
Zhou Y; Chen Y; Tong L; Xie H; Wen W; Zhang J; Xi Y; Shen Y; Geng M; Wang Y; Jiang H; Luo C; Lin L; Ding J
J Cell Mol Med; 2012 Oct; 16(10):2321-30. PubMed ID: 22304225
[TBL] [Abstract][Full Text] [Related]
6. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
7. A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.
Liu Y; He Y; Yang F; Cong X; Wang J; Peng S; Gao D; Wang W; Lan L; Ying X; Liu M; Chen Y; Yi Z
Sci China Life Sci; 2017 Feb; 60(2):202-214. PubMed ID: 28194552
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways
Zhang X; Zhang Y; Jia Y; Qin T; Zhang C; Li Y; Huang C; Liu Z; Wang J; Li K
Cancer Biol Med; 2020 May; 17(2):418-432. PubMed ID: 32587778
[No Abstract] [Full Text] [Related]
9. [Effects and mechanisms of Xiao-Ai-Ping injection on angiogenesis].
Wang MJ; Du DY; Fan W; Zhang C; Liu Y; Fan JH; Yuan ST; Lin SS
Yao Xue Xue Bao; 2016 Feb; 51(2):309-15. PubMed ID: 29856586
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis.
Lim HN; Jang JP; Han JM; Jang JH; Ahn JS; Jung HJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498688
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of inhibition of tumor angiogenesis by beta-hydroxyisovalerylshikonin.
Komi Y; Suzuki Y; Shimamura M; Kajimoto S; Nakajo S; Masuda M; Shibuya M; Itabe H; Shimokado K; Oettgen P; Nakaya K; Kojima S
Cancer Sci; 2009 Feb; 100(2):269-77. PubMed ID: 19200258
[TBL] [Abstract][Full Text] [Related]
13. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
14. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
[TBL] [Abstract][Full Text] [Related]
15. Oroxyloside inhibits angiogenesis through suppressing internalization of VEGFR2/Flk-1 in endothelial cells.
Zhao K; Li X; Lin B; Yang D; Zhou Y; Li Z; Guo Q; Lu N
J Cell Physiol; 2018 Apr; 233(4):3454-3464. PubMed ID: 28926106
[TBL] [Abstract][Full Text] [Related]
16. α-Melanocyte-stimulating hormone inhibits angiogenesis through attenuation of VEGF/VEGFR2 signaling pathway.
Weng WT; Huang SC; Ma YL; Chan HH; Lin SW; Wu JC; Wu CY; Wen ZH; Wang EM; Wu CL; Tai MH
Biochim Biophys Acta; 2014 Jun; 1840(6):1850-60. PubMed ID: 24530634
[TBL] [Abstract][Full Text] [Related]
17. A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.
Tate CM; Mc Entire J; Pallini R; Vakana E; Wyss L; Blosser W; Ricci-Vitiani L; D'Alessandris QG; Morgante L; Giannetti S; Larocca LM; Todaro M; Benfante A; Colorito ML; Stassi G; De Maria R; Rowlinson S; Stancato L
PLoS One; 2015; 10(4):e0125697. PubMed ID: 25919028
[TBL] [Abstract][Full Text] [Related]
18. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling.
Kano MR; Morishita Y; Iwata C; Iwasaka S; Watabe T; Ouchi Y; Miyazono K; Miyazawa K
J Cell Sci; 2005 Aug; 118(Pt 16):3759-68. PubMed ID: 16105884
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
20. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
